Royalty Pharma plc (NASDAQ: RPRX) reported Q2 cash receipts of $536 million versus the consensus estimate of $532.56 million.

GUIDANCE:

Royalty Pharma plc sees FY2022 adjusted cash receipts $2.275-2.35 billion, versus the consensus of $2.28 billion.

For earnings history and earnings-related data on Royalty Pharma plc (RPRX) click here.